ImmunityBio (IBRX) vs Revolution Medicines (RVMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Revolution Medicines (RVMD) has outperformed ImmunityBio (IBRX) over the past year, gaining 293.4% versus a gain of 291.7%. Over five years, RVMD leads with a +598.0% price change compared with +6.6% for IBRX. Revolution Medicines is the larger company by market cap ($40.67 billion vs $11.14 billion), about 3.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBRX | RVMD |
|---|---|---|
| Share price | $10.51 | $189.76 |
| Market cap | $11.14B | $40.67B |
| 1-day change | +6.05% | +0.87% |
| YTD return | +400.51% | +136.18% |
| 1-year return | +291.70% | +293.39% |
| 5-year return | +6.56% | +598.03% |
| EPS (TTM) | $-0.96 | $-8.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $113.29M | $0 |
| Revenue growth (YoY) | +668.31% | — |
| Net income (latest FY) | $-351.40M | $-1.13B |
| Gross margin | 99.34% | — |
| Operating margin | -226.00% | — |
| Net margin | -310.18% | — |
| 52-week high | $12.43 | $224.31 |
| 52-week low | $1.95 | $47.28 |
| Distance from 52-week high | -15.45% | -15.40% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +21.31% | +36.40% |
| Average volume | 10.28M | 1.93M |
| Shares outstanding | 1.06B | 214.34M |
| Employees | 684 | 883 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Revolution Medicines is about 3.7 times larger than ImmunityBio by market value ($40.67B vs $11.14B).
About ImmunityBio
IBRX stock →ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees
About Revolution Medicines
RVMD stock →Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 883 employees
IBRX vs RVMD FAQ
Which is bigger, ImmunityBio or Revolution Medicines?
Revolution Medicines (RVMD) is larger, with a market capitalization of $40.67B compared with $11.14B for ImmunityBio (IBRX).
Which stock has performed better over the past year, IBRX or RVMD?
RVMD returned +293.39% over the past 12 months, compared with +291.70% for IBRX (price return, excluding dividends). Past performance does not predict future results.
Are ImmunityBio and Revolution Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.